NASDAQ:SCPH scPharmaceuticals (SCPH) Stock Forecast, Price & News $7.12 +0.11 (+1.57%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$6.85▼$7.1550-Day Range$7.00▼$8.4652-Week Range$3.68▼$12.75Volume180,358 shsAverage Volume418,433 shsMarket Capitalization$255.32 millionP/E RatioN/ADividend YieldN/APrice Target$19.29 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability scPharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside170.9% Upside$19.29 Price TargetShort InterestBearish29.17% of Float Sold ShortDividend StrengthN/ASustainability-0.49Upright™ Environmental ScoreNews Sentiment1.38Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.40) to ($1.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector536th out of 972 stocksPharmaceutical Preparations Industry249th out of 451 stocks 3.5 Analyst's Opinion Consensus RatingscPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.29, scPharmaceuticals has a forecasted upside of 170.9% from its current price of $7.12.Amount of Analyst CoveragescPharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted29.17% of the float of scPharmaceuticals has been sold short.Short Interest Ratio / Days to CoverscPharmaceuticals has a short interest ratio ("days to cover") of 23.6, which indicates bearish sentiment.Change versus previous monthShort interest in scPharmaceuticals has recently increased by 2.38%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldscPharmaceuticals does not currently pay a dividend.Dividend GrowthscPharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorescPharmaceuticals has received a 75.76% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " product. See details.Environmental SustainabilityThe Environmental Impact score for scPharmaceuticals is -0.49. Previous Next 2.4 News and Social Media Coverage News SentimentscPharmaceuticals has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for scPharmaceuticals this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added scPharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, scPharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.68% of the stock of scPharmaceuticals is held by insiders.Percentage Held by Institutions79.60% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for scPharmaceuticals are expected to grow in the coming year, from ($1.40) to ($1.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of scPharmaceuticals is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of scPharmaceuticals is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioscPharmaceuticals has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About scPharmaceuticals (NASDAQ:SCPH) StockscPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Read More SCPH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCPH Stock News HeadlinesSeptember 27, 2023 | msn.comscPharmaceuticals: Furoscix, Charting A Bright Future With FDA's Nod For CKDSeptember 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Henry Schein (HSIC) and scPharmaceuticals (SCPH)September 29, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 19, 2023 | finance.yahoo.comscPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth InitiativesSeptember 13, 2023 | msn.comSizing Up scPharmaceuticalsSeptember 8, 2023 | msn.comCraig-Hallum Initiates Coverage of scPharmaceuticals (SCPH) with Buy RecommendationSeptember 5, 2023 | finance.yahoo.comscPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 12, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sientra (SIEN) and scPharmaceuticals (SCPH)September 29, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.August 10, 2023 | msn.comscPharmaceuticals GAAP EPS of -$0.36 beats by $0.01, revenue of $1.63M beats by $0.01MAugust 10, 2023 | finance.yahoo.comscPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 10, 2023 | finance.yahoo.comScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue EstimatesAugust 3, 2023 | finance.yahoo.comscPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023August 1, 2023 | finance.yahoo.comscPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication ExpansionJuly 22, 2023 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on scPharmaceuticals (SCPH)July 19, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for scPharmaceuticalsJuly 18, 2023 | finance.yahoo.comscPharmaceuticals, Inc. (SCPH) Loses -21.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerJune 30, 2023 | msn.comscPharmaceuticals: Oversold Territory, Drug Launch Still Looks RobustJune 23, 2023 | finance.yahoo.comscPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® IndexesJune 13, 2023 | fool.comscPharmaceuticals (NASDAQ: SCPH)June 8, 2023 | msn.comAnalyst Ratings for scPharmaceuticalsMay 29, 2023 | markets.businessinsider.comSVB Securities Sticks to Its Buy Rating for scPharmaceuticals (SCPH)May 20, 2023 | msn.comscPharmaceuticals: Furoscix Firing On All Cylinders In Q1, Bullish Than EverMay 15, 2023 | marketwatch.comLarge Volume Wearable Injectors Market Forthcoming Trends and Share Analysis by 2031May 13, 2023 | marketwatch.com8-K: scPharmaceuticals Inc.May 13, 2023 | finance.yahoo.comscPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2023 Earnings Call TranscriptMay 12, 2023 | finanznachrichten.descPharmaceuticals, Inc.: scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateSee More Headlines Receive SCPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SCPH Company Calendar Last Earnings8/10/2023Today9/29/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SCPH CUSIPN/A CIK1604950 Webwww.scpharma.com Phone(617) 517-0730FaxN/AEmployees96Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.29 High Stock Price Forecast$25.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+170.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,840,000.00 Net MarginsN/A Pretax Margin-1,209.78% Return on Equity-73.77% Return on Assets-43.25% Debt Debt-to-Equity Ratio0.60 Current Ratio17.12 Quick Ratio16.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / Book3.37Miscellaneous Outstanding Shares35,860,000Free Float34,179,000Market Cap$255.32 million OptionableNot Optionable Beta0.18 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. John H. Tucker (Age 60)Pres, CEO, Principal Exec. Officer & Director Comp: $912.2kMs. Rachael Nokes (Age 48)CFO & Principal Accounting Officer Comp: $496.45kMr. Michael D. HassmanSr. VP of Technical OperationsKatherine TaudvinVP of Corp. Affairs & HRDr. John Mohr Pharm.D.Sr. VP of Clinical Devel. & Medical AffairsSteve ParsonsSr. VP of CommercialMore ExecutivesKey CompetitorsVanda PharmaceuticalsNASDAQ:VNDAAtea PharmaceuticalsNASDAQ:AVIRReneo PharmaceuticalsNASDAQ:RPHMXeris BiopharmaNASDAQ:XERSLexicon PharmaceuticalsNASDAQ:LXRXView All CompetitorsInsiders & InstitutionsBarclays PLCSold 67,692 shares on 9/21/2023Ownership: 0.016%Alberta Investment Management CorpBought 111,410 shares on 8/24/2023Ownership: 0.311%Osaic Holdings Inc.Bought 48,191 shares on 8/21/2023Ownership: 0.240%California State Teachers Retirement SystemBought 9,606 shares on 8/21/2023Ownership: 0.027%Nuveen Asset Management LLCBought 90,503 shares on 8/16/2023Ownership: 0.252%View All Insider TransactionsView All Institutional Transactions SCPH Stock - Frequently Asked Questions Should I buy or sell scPharmaceuticals stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCPH shares. View SCPH analyst ratings or view top-rated stocks. What is scPharmaceuticals' stock price forecast for 2023? 6 analysts have issued twelve-month price objectives for scPharmaceuticals' shares. Their SCPH share price forecasts range from $13.00 to $25.00. On average, they predict the company's share price to reach $19.29 in the next year. This suggests a possible upside of 170.9% from the stock's current price. View analysts price targets for SCPH or view top-rated stocks among Wall Street analysts. How have SCPH shares performed in 2023? scPharmaceuticals' stock was trading at $7.17 at the beginning of the year. Since then, SCPH stock has decreased by 0.7% and is now trading at $7.12. View the best growth stocks for 2023 here. When is scPharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our SCPH earnings forecast. How were scPharmaceuticals' earnings last quarter? scPharmaceuticals Inc. (NASDAQ:SCPH) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.01. The firm earned $1.64 million during the quarter, compared to the consensus estimate of $1.55 million. What other stocks do shareholders of scPharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other scPharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), ImmunoGen (IMGN), VBI Vaccines (VBIV), Selecta Biosciences (SELB), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX). When did scPharmaceuticals IPO? (SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. What is scPharmaceuticals' stock symbol? scPharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH." How do I buy shares of scPharmaceuticals? Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is scPharmaceuticals' stock price today? One share of SCPH stock can currently be purchased for approximately $7.12. How much money does scPharmaceuticals make? scPharmaceuticals (NASDAQ:SCPH) has a market capitalization of $255.32 million. The company earns $-36,840,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. How can I contact scPharmaceuticals? scPharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The official website for the company is www.scpharma.com. The company can be reached via phone at (617) 517-0730 or via email at tignelzi@scpharma.com. This page (NASDAQ:SCPH) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.